Literature DB >> 19277774

Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients.

Adrian A Indar1, Tonia M Young-Fadok, Jacques Heppell, Jonathan E Efron.   

Abstract

BACKGROUND: The aim of the present study was to examine the early outcome in patients undergoing intestinal resection for Crohn's disease (CD) while they are receiving perioperative immunosuppressive medication.
METHODS: We reviewed patients with CD undergoing intestinal surgery from 1999 to 2007. Demographics and relevant perioperative information, including medication, were extracted from patient charts. Statistical analysis was performed using Fisher's exact test.
RESULTS: During the course of the study period 112 with Crohn's disease underwent intestinal resection, and 69 of them were receiving perioperative medication (47, corticosteroids; 39, immunomodulators; and 17, anti-tumor necrosis factor-alpha antibodies). There were no deaths. Median blood loss was 137 ml. Twenty-two of the patients using perioperative medication (32%) experienced complications, 10 of which were major. The major complications occurred in 3 of the 43 patients (7%) who were not receiving perioperative medications, in 5 of 38 patients (13%) who were receiving one drug, 4 of 28 patients (14%) receiving two drugs, and 1 of 3 patients (33%) receiving three drugs. Thus the occurrence of major complications was not significantly greater in patients receiving perioperative medication. Risk factors for a major complication were intraoperative blood loss >400 ml (P < 0.003) and emergency surgery (P < 0.005).
CONCLUSIONS: The occurrence of complications in Crohn's disease patients undergoing intestinal resection was not associated with the use of immunosuppressive medication. However, emergency surgery and blood loss were risk factors, and reflect the difficulty of surgery in this group of patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19277774     DOI: 10.1007/s00268-009-9957-x

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  14 in total

1.  Risk factors for intra-abdominal sepsis after surgery in Crohn's disease.

Authors:  T Yamamoto; R N Allan; M R Keighley
Journal:  Dis Colon Rectum       Date:  2000-08       Impact factor: 4.585

Review 2.  Azathioprine for maintaining remission of Crohn's disease.

Authors:  D C Pearson; G R May; G Fick; L R Sutherland
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 3.  Short-term outcomes after laparoscopic ileocolic resection for Crohn's disease. A systematic review.

Authors:  Sebastiaan W Polle; Jan Wind; Dirk T Ubbink; Daan W Hommes; Dirk J Gouma; Willem A Bemelman
Journal:  Dig Surg       Date:  2006-12-12       Impact factor: 2.588

4.  Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery.

Authors:  J Cosnes; I Nion-Larmurier; L Beaugerie; P Afchain; E Tiret; J-P Gendre
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

5.  Early complications following surgical treatment for Crohn's disease.

Authors:  T M Heimann; A J Greenstein; L Mechanic; A H Aufses
Journal:  Ann Surg       Date:  1985-04       Impact factor: 12.969

6.  Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.

Authors:  Chelliah R Selvasekar; Robert R Cima; David W Larson; Eric J Dozois; Jeffrey R Harrington; William S Harmsen; Edward V Loftus; William J Sandborn; Bruce G Wolff; John H Pemberton
Journal:  J Am Coll Surg       Date:  2007-05       Impact factor: 6.113

7.  Risks of intestinal anastomoses in Crohn's disease.

Authors:  S Post; M Betzler; B von Ditfurth; G Schürmann; P Küppers; C Herfarth
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

Review 8.  Impact of blood loss on outcome after liver resection.

Authors:  Marieke T de Boer; I Quintus Molenaar; Robert J Porte
Journal:  Dig Surg       Date:  2007-07-27       Impact factor: 2.588

9.  Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?

Authors:  Stefanie J Schluender; Andrew Ippoliti; Marla Dubinsky; Eric A Vasiliauskas; Konstantinos A Papadakis; Ling Mei; Stephan R Targan; Phillip R Fleshner
Journal:  Dis Colon Rectum       Date:  2007-11       Impact factor: 4.585

10.  Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.

Authors:  Jean Frédéric Colombel; Edward V Loftus; William J Tremaine; John H Pemberton; Bruce G Wolff; Tonia Young-Fadok; William S Harmsen; Cathy D Schleck; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2004-05       Impact factor: 10.864

View more
  20 in total

1.  Effects of minimizing access trauma in laparoscopic colectomy in patients with IBD.

Authors:  Claudia Seifarth; Joerg-Peter Ritz; Anton Kroesen; Heinz J Buhr; Joern Groene
Journal:  Surg Endosc       Date:  2014-08-27       Impact factor: 4.584

Review 2.  [Refractory inflammatory bowel disease: surgical challenges].

Authors:  H J Buhr; A J Kroesen
Journal:  Chirurg       Date:  2013-11       Impact factor: 0.955

3.  Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease.

Authors:  Miguel Regueiro; Sandra El-Hachem; Kevin E Kip; Wolfgang Schraut; Leonard Baidoo; Andrew Watson; Jason Swoger; Marc Schwartz; Arthur Barrie; Marilyn Pesci; David Binion
Journal:  Dig Dis Sci       Date:  2011-06-17       Impact factor: 3.199

4.  Preoperative risk evaluation of postoperative morbidity in IBD patients--impact of the POSSUM score.

Authors:  Jan-Hendrik Egberts; Antje Stroeh; Ibrahim Alkatout; Freya A Goumas; Phillipp A Brand; Clemens Schafmayer; Thomas Becker; Bodo Schniewind
Journal:  Int J Colorectal Dis       Date:  2011-04-28       Impact factor: 2.571

Review 5.  Inflammatory bowel disease: perioperative pharmacological considerations.

Authors:  Ajay Kumar; Moises Auron; Ashish Aneja; Franziska Mohr; Alok Jain; Bo Shen
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

Review 6.  Perioperative Considerations in Crohn Disease and Ulcerative Colitis.

Authors:  T Paul Nickerson; Amit Merchea
Journal:  Clin Colon Rectal Surg       Date:  2016-06

7.  [Proctocolectomy in ulcerative colitis : is a multistep procedure in cases of immunosuppression advisable?].

Authors:  C Seifarth; J Gröne; N Slavova; B Siegmund; H J Buhr; J-P Ritz
Journal:  Chirurg       Date:  2013-09       Impact factor: 0.955

8.  Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience.

Authors:  Chaya Shwaartz; Adam C Fields; Maximiliano Sobrero; Brian D Cohen; Celia M Divino
Journal:  J Gastrointest Surg       Date:  2016-07-12       Impact factor: 3.452

Review 9.  Adverse events in IBD: to stop or continue immune suppressant and biologic treatment.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-02-04       Impact factor: 3.869

Review 10.  Biologic therapy and surgery for crohn disease.

Authors:  E Carter Paulson
Journal:  Clin Colon Rectal Surg       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.